Orphan Drug Designation For ALD-10, Novel Stem Cell Therapy For Patients With Metabolic Disorders Undergoing Umbilical Cord Blood Transplantation

Aldagen, Inc. today announced that it has received orphan drug designation for ALD-101 from the U.S. Food and Drug Administration (FDA). The designation was granted for the use of ALD-101 to improve patient outcomes by decreasing time to platelet and neutrophil engraftment in patients with inherited metabolic disorders undergoing umbilical cord blood transplantation.

More: continued here

Filed under: Blood on November 3rd, 2008